Pertussis vaccines

Vaccines

Volumn , Issue , 2008, Pages 467-517

  Edwards, Kathryn M ^a   Decker, Michael D ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85158927984     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3611-1.50025-8     Document Type: Chapter

References (506)

1. WH Holmes (1940) Bacillary and rickettsial infections, acute and chronic; a text-book, black death to white plague New York: The Macmillan company 395-398.
2. A Hardy (1993) Whooping Cough. KF Kiple (Eds) Paper presented at: The Cambridge World History of Human Disease New York: Cambridge University Press 1094-1096.
3. J Bordet and O Gengou (1906) Le microbe de la coqueluche. Ann Inst Pasteur 20 731-741.
4. J Cherry, P Brunnel and G Golden (1988) Report of the Task Force on Pertussis and Pertussis Immunization, 1988. Pediatrics 81(suppl), 933-984.
5. Pertussis vaccination use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 46(RR-7), 1-25.
6. Pertussis – United States, 1997–2000. MMWR Morb Mortal Wkly Rep 51(4), 73-76.
7. KR Broder, MM Cortese, JK Iskander, et al. (2006) Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55(RR-3), 1-34.
8. Preventing Tetanus Diphtheria, and Pertussis Among Adults Use of to diagnose pertussis (66). Use of PCR tests with low specificity can result in unnecessary investigation and treatment of persons with false-positive PCR test. www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm?s_cid=rr5517a1_e
9. MM Cortese, AL Baughman, K Brown and P Srivastava (2007 Mar) A “new age” in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 32(3), 177-185.
10. Pertussis Reported Cases (interactive online data table). Geneva: World Health Organization. Online. Available at: www.nt.who.int/vaccines/globalsummary/timeseries/TSincidencePer.htm Accessed August 8, 2002
11. G Zackrisson, J Taranger and B Trollfors (1990) History of whooping cough in nonvaccinated Swedish children, related to serum antibodies to pertussis toxin and filamentous hemagglutinin. J Pediatr 116(2), 190-194.
12. U Heininger, K Klich, K Stehr and JD Cherry (1997) Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics 100(6), E10.
13. JH Lapin (1943) Whooping Cough Springfield, Ill, Baltimore, Md.: C.C. Thomas
14. NB Halasa, FE Barr, JE Johnson and KM Edwards (2003) Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role. Pediatrics 112(6 Pt 1), 1274-1278.
15. GD Williams, A Numa, J Sokol, et al. (1998) ECLS in pertussis: does it have a role. Intensive Care Med 24(10), 1089-1092.
16. N Wortis, PM Strebel, M Wharton, et al. (1996) Pertussis deaths: report of 23 cases in the United States, 1992 and 1993. Pediatrics 97(5), 607-612.
17. CD Sreenan and H Osiovich (2001) Neonatal pertussis requiring extracorporeal membrane oxygenation. Pediatr Surg Int 17(2–3), 201-203.
18. L Chan (1997) Cough and respiratory distress in a two-month-old infant. Pediatr Infect Dis J 16(6), 631-632, 634–635.
19. J Gillis, T Grattan-Smith and H Kilham (1988) Artificial ventilation in severe pertussis. Arch Dis Child 63(4), 364-367.
20. GD Goulin, KM Kaya and JS Bradley (1993) Severe pulmonary hypertension associated with shock and death in infants infected with Bordetella pertussis. Crit Care Med 21(11), 1791-1794.
21. C Pierce, N Klein and M Peters (2000) Is leukocytosis a predictor of mortality in severe pertussis infection. Intensive Care Med 26(10), 1512-1514.
22. K Plott and F Pascual (2002) Pertussis deaths—United States 2000. MMWR 51 616-618.
23. ID Johnston, JM Bland, D Ingram, et al. (1986) Effect of whooping cough in infancy on subsequent lung function and bronchial reactivity. Am Rev Respir Dis 134(2), 270-275.
24. CC Grant, EJ McKay, A Simpson and D Buckley (1998) Pertussis encephalopathy with high cerebrospinal fluid antibody titers to pertussis toxin and filamentous hemagglutinin. Pediatrics 102(4 Pt 1), 986-990.
25. LK Mikelova, SA Halperin, D Scheifele, et al. (2003) Predictors of death in infants hospitalized with pertussis: a case-control study of 16 pertussis deaths in Canada. J Pediatr 143(5), 576-581.
26. A Litvak, H Gibel and S Rosenthal (1948) Cerebral complications in pertussis. J Pediatr 32 357-379.
27. Great Britain (1981) Committee on Safety of Medicines., Great Britain. Joint Committee on Vaccination and Immunisation., Great Britain. Dept. of Health and Social Security. Whooping cough: reports from the Committee on Safety of Medicines and the Joint Committee on Vaccination and Immunisation London: H.M.S.O. 184. xiii
28. H Zellweger (1959) Pertussis encephalopathy. Arch Pediatr 76 381-386.
29. JD Nelson (1978) The changing epidemiology of pertussis in young infants. The role of adults as reservoirs of infection. Am J Dis Child 132(4), 371-373.
30. G De Serres, R Shadmani, B Duval, et al. (2000) Morbidity of pertussis in adolescents and adults. J Infect Dis 182(1), 174-179.
31. KM Bisgard, FB Pascual, KR Ehresmann, et al. (2004) Infant pertussis: who was the source. Pediatr Infect Dis J 23(11), 985-989.
32. AM Wendelboe, E Njamkepo, A Bourillon, et al. (2007 Apr) Infant Pertussis Study Group. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 26(4), 293-299.
33. LD Senzilet, SA Halperin, JS Spika, et al. (2001) Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis 32(12), 1691-1697.
34. S Schmitt-Grohe, JD Cherry, U Heininger, et al. (1995) Pertussis in German adults. Clin Infect Dis 21(4), 860-866.
35. S Postels-Multani, HJ Schmitt, CH Wirsing von Konig, et al. (1995) Symptoms and complications of pertussis in adults. Infection 23(3), 139-142.
36. SS Long, HW Lischner, A Deforest and JL Clark (1990) Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 9(10), 700-705.
37. BA Cromer, J Goydos, J Hackell, et al. (1993) Unrecognized pertussis infection in adolescents. Am J Dis Child 147(5), 575-577.
38. SS Long, CJ Welkon and JL Clark (1990) Widespread silent transmission of pertussis in families: antibody correlates of infection and symptomatology. J Infect Dis 161(3), 480-486.
39. T Eidlitz-Markus and A Zeharia (2005) Bordetella pertussis as a trigger of migraine without aura. Pediatr Neurol 33(4), 283-284.
40. DM Skowronski, JA Buxton, M Hestrin, et al. (2003) Carotid artery dissection as a possible severe complication of pertussis in an adult: clinical case report and review. Clin Infect Dis 36(1), e1-e4.
41. P Jenkins and SW Clarke (1981) Cough syncope: a complication of adult whooping cough. Br J Dis Chest 75(3), 311-313.
42. SA Halperin and TJ Marrie (1991) Pertussis encephalopathy in an adult: case report and review. Rev Infect Dis 13(6), 1043-1047.
43. DW MacLean (1982) Adults with pertussis. J R Coll Gen Pract 32(238), 298-300.
44. Fatal case of unsuspected pertussis diagnosed from a blood culture—Minnesota, 2003. MMWR Morb Mortal Wkly Rep 53(6), 131-132.
45. CR Manclark and JL Cowell (1984) Pertussis. R Germanier (Eds) Bacterial vaccines Orlando: Academic Press 69-106.
46. W Kloos, N Mohapatra and W Dobrogosz (1981) Deoxyribonucleotide sequence relationship among Bordetella species. Int J Syst Bacteriol 31 173-176.
47. ON Bjornstad and ET Harvill (2005) Evolution and emergence of Bordetella in humans. Trends Microbiol 13(8), 355-359.
48. B Arico and R Rappuoli (1987) Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes. J Bacteriol 169(6), 2847-2853.
49. S Mattoo, AK Foreman-Wykert, PA Cotter and JF Miller (2001) Mechanisms of Bordetella pathogenesis. Front Biosci 6 E168-E186.
50. DA Diavatopoulos, CA Cummings, LM Schouls, et al. (2005) Bordetella pertussis, the causative agent of whooping cough, evolved from a distinct, human-associated lineage of B. bronchiseptica. PLoS Pathog 1(4), e45.
51. YW Tang, MK Hopkins, CP Kolbert, et al. (1998) Bordetella holmesii-like organisms associated with septicemia, endocarditis, and respiratory failure. Clin Infect Dis 26(2), 389-392.
52. WK Yih, EA Silva, J Ida, N Harrington, et al. (1999) Bordetella holmesii-like organisms isolated from Massachusetts patients with pertussis-like symptoms. Emerg Infect Dis 5(3), 441-443.
53. SW Lindquist, DJ Weber, ME Mangum, et al. (1995) Bordetella holmesii sepsis in an asplenic adolescent. Pediatr Infect Dis J 14(9), 813-815.
54. CW Shepard, MI Daneshvar, RM Kaiser, et al. (2004) Bordetella holmesii bacteremia: a newly recognized clinical entity among asplenic patients. Clin Infect Dis 38(6), 799-804.
55. BT Cookson, P Vandamme, LC Carlson, et al. (1994) Bacteremia caused by a novel Bordetella species, ‘B. hinzii.’. J Clin Microbiol 32(10), 2569-2571.
56. G Funke, T Hess, A von Graevenitz and P Vandamme (1996) Characteristics of Bordetella hinzii strains isolated from a cystic fibrosis patient over a 3-year period. J Clin Microbiol 34(4), 966-969.
57. E Tuomanen (1988) Bordetella pertussis adhesins. AC Wardlaw, R Parton (Eds) Pathogenesis and Immunity in Pertussis New York: John 75-94.
58. A Weiss (1997) Mucosal immune defenses and the response of Bordetella pertussis. ASM News 63 22-28.
59. H Sato and Y Sato (1991) Relationship between structure and biological and protective activities of pertussis toxin. Dev Biol Stand 73 121-132.
60. KM Farizo, T Huang and DL Burns (2000) Importance of holotoxin assembly in PT-mediated secretion of pertussis toxin from Bordetella pertussis. Infect Immun 68(7), 4049-4054.
61. M Tamura, K Nogimori, S Murai, et al. (1982) Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 21(22), 5516-5522.
62. SA Halperin, TB Issekutz and A Kasina (1991) Modulation of Bordetella pertussis infection with monoclonal antibodies to pertussis toxin. J Infect Dis 163(2), 355-361.
63. L Nencioni, MG Pizza, G Volpini, et al. (1991) Properties of the B oligomer of pertussis toxin. Infect Immun 59(12), 4732-4734.
64. M Watanabe (1984) Biological activities of pertussigen from Bordetella pertussis strains of various agglutinogen types. Microbiol Immunol 28(5), 509-515.
65. SZ Hausman, JD Cherry, U Heininger, et al. (1996) Analysis of proteins encoded by the ptx and ptl genes of Bordetella bronchiseptica and Bordetella parapertussis. Infect Immun 64(10), 4020-4026.
66. GS Kirimanjeswara, LM Agosto, MJ Kennett, et al. (2005) Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 115(12), 3594-3601.
67. NH Carbonetti, GV Artamonova, RM Mays and ZE Worthington (2003) Pertussis toxin plays an early role in respiratory tract colonization by Bordetella pertussis. Infect Immun 71(11), 6358-6366.
68. NH Carbonetti, GV Artamonova, C Andreasen and N Bushar (2005) Pertussis toxin and adenylate cyclase toxin provide a one-two punch for establishment of Bordetella pertussis infection of the respiratory tract. Infect Immun 73(5), 2698-2703.
69. T Toyota, Y Kai, M Kakizaki, et al. (1980) Effects of islet-activating protein (IAP) on blood glucose and plasma insulin in healthy volunteers (phase 1 studies). Tohoku J Exp Med 130(2), 105-116.
70. M Pittman (1984) The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis 3(5), 467-486.
71. H Sato and Y Sato (1984) Bordetella pertussis infection in mice: correlation of specific antibodies against two antigens, pertussis toxin, and filamentous hemagglutinin with mouse protectivity in an intracerebral or aerosol challenge system. Infect Immun 46(2), 415-421.
72. JL Arciniega, RD Shahin, WN Burnette, et al. (1991) Contribution of the B oligomer to the protective activity of genetically attenuated pertussis toxin. Infect Immun 59(10), 3407-3410.
73. P McGuirk, C McCann and KH Mills (2002) Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 195(2), 221-231.
74. T Abramson, H Kedem and DA Relman (2001) Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin. Infect Immun 69(4), 2650-2658.
75. E Tuomanen, A Weiss, R Rich, et al. (1985) Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev Biol Stand 61 197-204.
76. E Tuomanen and A Weiss (1985) Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J Infect Dis 152(1), 118-125.
77. M Oda, JL Cowell, DG Burstyn and CR Manclark (1984) Protective activities of the filamentous hemagglutinin and the lymphocytosis-promoting factor of Bordetella pertussis in mice. J Infect Dis 150(6), 823-833.
78. Q He, MK Viljanen, RM Olander, et al. (1994) Antibodies to filamentous hemagglutinin of Bordetella pertussis and protection against whooping cough in schoolchildren. J Infect Dis 170(3), 705-708.
79. CA Geuijen, RJ Willems, M Bongaerts, et al. (1997) Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect Immun 65(10), 4222-4228.
80. PA Cotter, MH Yuk, S Mattoo, et al. (1998) Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect Immun 66(12), 5921-5929.
81. TN Stanbridge and NW Preston (1974) Variation of serotype in strains of Bordetella pertussis. J Hyg (Lond) 73(2), 305-310.
82. NW Preston and TN Stanbridge (1972) Efficacy of pertussis vaccines: a brighter horizon. Br Med J 3(824), 448-451.
83. C Bronne-Shanbury, D Miller and AF Standfast (1976) The serotypes of Bordetella pertussis isolated in Great Britain between 1941 and 1968 and a comparison with the serotypes observed in other countries over this period. J Hyg (Lond) 76(2), 265-275.
84. Efficacy of whooping-cough vaccines used in the United Kingdon befroe 1968. Br Med J 1 259-262.
85. NW Preston (1976) Prevalent serotypes of Bordetella pertussis in non-vaccinated communities. J Hyg (Lond) 77(1), 85-91.
86. J Storsaeter, HO Hallander, L Gustafsson and P Olin (1998) Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916.
87. RJ Willems, J Kamerbeek, CA Geuijen, et al. (1998) The efficacy of a whole cell pertussis vaccine and fimbriae against Bordetella pertussis and Bordetella parapertussis infections in a respiratory mouse model. Vaccine 16(4), 410-416.
88. ME Rodriguez, SM Hellwig, ML Perez Vidakovics, et al. (2006) Bordetella pertussis attachment to respiratory epithelial cells can be impaired by fimbriae-specific antibodies. FEMS Immunol Med Microbiol 46(1), 39-47.
89. WHO Expert Committee on Biological Standardization. Paper presented at: World Health Organ Tech Rep Ser, 1990.
90. MJ Brennan, ZM Li, JL Cowell, et al. (1988) Identification of a 69-kilodalton nonfimbrial protein as an agglutinogen of Bordetella pertussis. Infect Immun 56(12), 3189-3195.
91. P Novotny, AP Chubb, K Cownley and IG Charles (1991) Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine. J Infect Dis 164(1), 114-122.
92. P Emsley, G McDermott, IG Charles, et al. (1994) Crystallographic characterization of pertactin, a membrane-associated protein from Bordetella pertussis. J Mol Biol 235(2), 772-773.
93. Leininger E, JG K, MJ B. Surface proteins of Bordetella pertussis: role in adherence. Proceedings of the Sixth International Symposium on Pertussis (DHHS Publication No. FDA 90–1164). Bethesda, MD: US Public Health Service; 1990:100–104.
94. Ewanowich CA, E L. Mechanisms of Bortella pertussis invasion of HeLa 229 cells. U.S Public Health Service. Proceedings of the Sixth International Symposium on Pertussis (DHHS Publication No. FDA 90–164. Bethesda, MD; 1990, 106–113
95. B Trollfors, G Zackrisson, J Taranger and T Lagergard (1992) Serum antibodies against a 69-kilodalton outer-membrane protein, pertactin, from Bordetella pertussis in nonvaccinated children with and without a history of clinical pertussis. J Pediatr 120(6), 924-926.
96. MG Thomas, K Redhead and HP Lambert (1989) Human serum antibody responses to Bordetella pertussis infection and pertussis vaccination. J Infect Dis 159(2), 211-218.
97. RD Shahin, MJ Brennan, ZM Li, et al. (1990) Characterization of the protective capacity and immunogenicity of the 69-kD outer membrane protein of Bordetella pertussis. J Exp Med 171(1), 63-73.
98. FR Mooi, H van Oirschot, K Heuvelman, et al. (1998) Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 66(2), 670-675.
99. E Njamkepo, F Rimlinger, S Thiberge and N Guiso (2002) Thirty-five years’ experience with the whole-cell pertussis vaccine in France: vaccine strains analysis and immunogenicity. Vaccine 20(9–10), 1290-1294.
100. C Weber, C Boursaux-Eude, G Coralie, et al. (2001) Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 39(12), 4396-4403.
101. AJ King, G Berbers, HF van Oirschot, et al. (2001) Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147(Pt 11), 2885-2895.
102. FR Mooi, IH van Loo and AJ King (2001) Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence. Emerg Infect Dis 7(3 Suppl), 526-528.
103. HO Hallander, A Advani, D Donnelly, et al. (2005) Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs. J Clin Microbiol 43(6), 2856-2865.
104. P Mastrantonio, P Spigaglia, H van Oirschot, et al. (1999) Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children. Microbiology 145(Pt 8), 2069-2075.
105. P Mastrantonio, M Cerquetti, R Cardines, et al. (1999) Immunogenicity issues in the quality control of the new acellular pertussis vaccines. Biologicals 27(2), 119-121.
106. Poolman J. Efficacy of Infanrix in promoting lung cancer clearance of B. pertussis strains expressing pertactin antigenic variants in a mouse respiratory model. abstr 234. Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 1999. 1999:356.
107. C Boursaux-Eude, S Thiberge, G Carletti and N Guiso (1999) Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine. Vaccine 17(20–21), 2651-2660.
108. EL Hewlett and G VM (1998) Adenylate cyclase toxin of Bordetella pertussis. AC Wardlaw, R Parton (Eds) Pathogenesis and Immunity in Pertussis New York: John Wiley 193-209.
109. EL Hewlett, GM Donato and MC Gray (2006) Macrophage cytotoxicity produced by adenylate cyclase toxin from Bordetella pertussis: more than just making cyclic. AMP! Mol Microbiol 59(2), 447-459.
110. Weiss A, M G, N A. Investigation of the role of Bordetella pertussis virulence factors in disease. Proceedings of the Sixth International Symposium on Pertussis (DHHS Publication No. FDA 90–164. Bethesda, MD: US Public Health Service, 1990; 1990:202–205.
111. JL Arciniega, EL Hewlett, FD Johnson, et al. (1991) Human serologic response to envelope-associated proteins and adenylate cyclase toxin of Bordetella pertussis. J Infect Dis 163(1), 135-142.
112. NMSMR Guiso (1990) Bordetella pertussis adenylate cyclase: a protective antigen against lethality and bacterial colonizations in murine respiratory and intracerebral models. Proceedings of the Sixth International Symposium on Pertussis (DHHS Publication No. FDA 90–164 Bethesda, MD: US Public Health Service 207-231.
113. BT Cookson, HL Cho, LA Herwaldt and WE Goldman (1989) Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infect Immun 57(7), 2223-2229.
114. WE Goldman (1988) Tracheal cytotoxin of Bordetella pertussis. AC Wardlaw, R Parton (Eds) Pathogenesis and Immunity in Pertussis New York: John Wiley 231-246.
115. BT Cookson, HL Cho, LA Herwaldt and WE Goldman (1989 Jul) Biological activities and chemical composition of purified tracheal cytotoxin of Bordetella pertussis. Infect Immun 57(7), 2223-2229.
116. Y Nakase and M Endoh (1988) Heat-labile toxin of Bordetella pertussis endotoxin. AC Wardlaw, R Parton (Eds) Pathogenesis and Immunity in Pertussis New York: John Wiley 211-229.
117. M Endoh, M Nagai, DL Burns, et al. (1990) Effects of exogenous agents on the action of Bordetella parapertussis heat-labile toxin on guinea pig skin. Infect Immun 58(5), 1456-1460.
118. RC Fernandez and AA Weiss (1994) Cloning and sequencing of a Bordetella pertussis serum resistance locus. Infect Immun 62(11), 4727-4738.
119. KD Elder and ET Harvill (2004) Strain-dependent role of BrkA during Bordetella pertussis infection of the murine respiratory tract. Infect Immun 72(10), 5919-5924.
120. DC Oliver and RC Fernandez (2001) Antibodies to BrkA augment killing of Bordetella pertussis. Vaccine 20(1–2), 235-241.
121. MG Barnes and AA Weiss (2002) Growth phase influences complement resistance of Bordetella pertussis. Infect Immun 70(1), 403-406.
122. R Chaby and M Croff (1988) Lipopolysaccharides of Bordetella pertussis endotoxin. AC Wardlaw, R Parton (Eds) Pathogenesis and Immunity in Pertussis New York: John Wiley 247-271.
123. ET Harvill, A Preston, PA Cotter, et al. (2000) Multiple roles for Bordetella lipopolysaccharide molecules during respiratory tract infection. Infect Immun 68(12), 6720-6728.
124. LJ Baraff, CR Manclark, JD Cherry, et al. (1989) Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr Infect Dis J 8(8), 502-507.
125. AA Weiss and EL Hewlett (1986) Virulence factors of Bordetella pertussis. Annu Rev Microbiol 40 661-686.
126. EL Hewlett (1997) Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J 16(4 Suppl), S78-S84.
127. JM Zhang, JL Cowell, AC Steven and CR Manclark (1985) Purification of serotype 2 fimbriae of Bordetella pertussis and their identification as a mouse protective antigen. Dev Biol Stand 61 173-185.
128. DL Confer and JW Eaton (1982) Phagocyte impotence caused by an invasive bacterial adenylate cyclase. Science 217(4563), 948-950.
129. LC Olson (1975) Pertussis. Medicine (Baltimore) 54(6), 427-469.
130. FM Muller, JE Hoppe and CH Wirsing von Konig (1997) Laboratory diagnosis of pertussis: state of the art in 1997. J Clin Microbiol 35(10), 2435-2443.
131. HO Hallander (1999) Microbiological and serological diagnosis of pertussis. Clin Infect Dis 28(Suppl 2), S99-S106.
132. CV Broome, DW Fraser and WJ English (1979) Pertussis–diagnostic methods and surveillance Bethesda, Md.: U. S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health; Washington: for sale by the Supt of Docs, U. S. Govt Print Off
133. PM Strebel, SL Cochi, KM Farizo, et al. (1993) Pertussis in Missouri: evaluation of nasopharyngeal culture, direct fluorescent antibody testing, and clinical case definitions in the diagnosis of pertussis. Clin Infect Dis 16(2), 276-285.
134. IM Onorato and SG Wassilak (1987) Laboratory diagnosis of pertussis: the state of the art. Pediatr Infect Dis J 6(2), 145-151.
135. SA Halperin, R Bortolussi and AJ Wort (1989) Evaluation of culture, immunofluorescence, and serology for the diagnosis of pertussis. J Clin Microbiol 27(4), 752-757.
136. HO Hallander, E Reizenstein, B Renemar, et al. (1993) Comparison of nasopharyngeal aspirates with swabs for culture of Bordetella pertussis. J Clin Microbiol 31(1), 50-52.
137. G Granstrom, B Wretlind and M Granstrom (1991) Diagnostic value of clinical and bacteriological findings in pertussis. J Infect 22(1), 17-26.
138. Placebo-controlled trial of two acellular pertussis vaccines in Sweden–protective efficacy and adverse events. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 1(8592), 955-960.
139. U Heininger, G Schmidt-Schlapfer, JD Cherry and K Stehr (2000) Clinical validation of a polymerase chain reaction assay for the diagnosis of pertussis by comparison with serology, culture, and symptoms during a large pertussis vaccine efficacy trial. Pediatrics 105(3), E31.
140. AJ Stadel (2000) Use of monoclonal fluorescent antibodies for the detection of B. pertussis and B. parapertussis. Am Clin Lab 19(3), 14.
141. CA Ewanowich, LW Chui, MG Paranchych, et al. (1993) Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology. J Clin Microbiol 31(7), 1715-1725.
142. Q He, J Mertsola, H Soini and MK Viljanen (1994) Sensitive and specific polymerase chain reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens. J Pediatr 124(3), 421-426.
143. G Schlapfer, JD Cherry, U Heininger, et al. (1995) Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J 14(3), 209-214.
144. P Olcen, A Backman, B Johansson, et al. (1992) Amplification of DNA by the polymerase chain reaction for the efficient diagnosis of pertussis. Scand J Infect Dis 24(3), 339-345.
145. E Reizenstein, S Lofdahl, M Granstrom, et al. (1992) Evaluation of an improved DNA probe for diagnosis of pertussis. Diagn Microbiol Infect Dis 15(7), 569-573.
146. EM Glare, JC Paton, RR Premier, et al. (1990) Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J Clin Microbiol 28(9), 1982-1987.
147. K Edelman, S Nikkari, O Ruuskanen, et al. (1996) Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr Infect Dis J 15(1), 54-57.
148. Q He, G Schmidt-Schlapfer, M Just, et al. (1996) Impact of polymerase chain reaction on clinical pertussis research: Finnish and Swiss experiences. J Infect Dis 174(6), 1288-1295.
149. L Knorr, JD Fox, PA Tilley and J Ahmed-Bentley (2006) Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection. BMC Infect Dis 6 62.
150. G Schmidt-Schlapfer, JG Liese, F Porter, et al. (1997) Polymerase chain reaction (PCR) compared with conventional identification in culture for detection of Bordetella pertussis in 7153 children. Clin Microbiol Infect 3(4), 462-467.
151. LM Sloan, MK Hopkins, PS Mitchell, et al. (2002) Multiplex LightCycler PCR assay for detection and differentiation of Bordetella pertussis and Bordetella parapertussis in nasopharyngeal specimens. J Clin Microbiol 40(1), 96-100.
152. K Kosters, M Riffelmann and CH Wirsing von Konig (2001) Evaluation of a real-time PCR assay for detection of Bordetella pertussis and B. parapertussis in clinical samples. J Med Microbiol 50(5), 436-440.
153. U Reischl, N Lehn, GN Sanden and MJ Loeffelholz (2001) Real-time PCR assay targeting IS481 of Bordetella pertussis and molecular basis for detecting Bordetella holmesii. J Clin Microbiol 39(5), 1963-1966.
154. PA Tilley, MV Kanchana, I Knight, et al. (2000) Detection of Bordetella pertussis in a clinical laboratory by culture, polymerase chain reaction, and direct fluorescent antibody staining; accuracy, and cost. Diagn Microbiol Infect Dis 37(1), 17-23.
155. MJ Loeffelholz, CJ Thompson, KS Long and MJ Gilchrist (1999) Comparison of PCR, culture, and direct fluorescent-antibody testing for detection of Bordetella pertussis. J Clin Microbiol 37(9), 2872-2876.
156. KE Templeton, SA Scheltinga, A van der Zee, et al. (2003) Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol 41(9), 4121-4126.
157. G Muyldermans, O Soetens, M Antoine, et al. (2005) External quality assessment for molecular detection of Bordetella pertussis in European laboratories. J Clin Microbiol 43(1), 30-35.
158. FA Lievano, MA Reynolds, AL Waring, et al. (2002) Issues associated with and recommendations for using PCR to detect outbreaks of pertussis. J Clin Microbiol 40(8), 2801-2805.
159. E Klement, L Uliel, I Engel, et al. (2003) An outbreak of pertussis among young Israeli soldiers. Epidemiol Infect 131(3), 1049-1054.
160. I Srugo, D Benilevi, R Madeb, et al. (2000) Pertussis infection in fully vaccinated children in day-care centers, Israel. Emerg Infect Dis 6(5), 526-529.
161. MC Fisher, SS Long, KL McGowan, et al. (1989) Outbreak of pertussis in a residential facility for handicapped people. J Pediatr 114(6), 934-939.
162. Meade B, Mink C, CR M. Serodiagnoisis of pertussis. Proceedings of the Sixth International Symposium on Pertussis. DHHS Publication No. FDA 90–164. Bethesda, MD: US Public Health Service, 1990:322–329.
163. CH Wirsing von Konig, D Gounis, S Laukamp, et al. (1999) Evaluation of a single-sample serological technique for diagnosing pertussis in unvaccinated children. Eur J Clin Microbiol Infect Dis 18(5), 341-345.
164. F Simondon, I Iteman, MP Preziosi, et al. (1998) Evaluation of an immunoglobulin G enzyme-linked immunosorbent assay for pertussis toxin and filamentous hemagglutinin in diagnosis of pertussis in Senegal. Clin Diagn Lab Immunol 5(2), 130-134.
165. RW Steketee, DG Burstyn, SG Wassilak, et al. (1988) A comparison of laboratory and clinical methods for diagnosing pertussis in an outbreak in a facility for the developmentally disabled. J Infect Dis 157(3), 441-449.
166. CM Mink, JD Cherry, P Christenson, et al. (1992) A search for Bordetella pertussis infection in university students. Clin Infect Dis 14(2), 464-471.
167. DG Addiss, JP Davis, BD Meade, et al. (1991) A pertussis outbreak in a Wisconsin nursing home. J Infect Dis 164(4), 704-710.
168. LA Cattaneo, GW Reed, DH Haase, et al. (1996) The seroepidemiology of Bordetella pertussis infections: a study of persons ages 1–65 years. J Infect Dis 173(5), 1256-1259.
169. A Giammanco, A Chiarini, T Stroffolini, et al. (1991) Seroepidemiology of pertussis in Italy. Rev Infect Dis 13(6), 1216-1220.
170. JD Cherry, SJ Chang, D Klein, et al. (2004) Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis 39(11), 1715-1718.
171. AL Baughman, KM Bisgard, KM Edwards, et al. (2004) Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States. Clin Diagn Lab Immunol 11(6), 1045-1053.
172. SA Halperin, R Bortolussi, D MacLean and N Chisholm (1989) Persistence of pertussis in an immunized population: results of the Nova Scotia Enhanced Pertussis Surveillance Program. J Pediatr 115(5 Pt 1), 686-693.
173. KM Edwards (2001) Is pertussis a frequent cause of cough in adolescents and adults. Should routine pertussis immunization be recommended? Clin Infect Dis 32(12), 1698-1699.
174. JI Ward, JD Cherry, SJ Chang, et al. (2005) Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med 353(15), 1555-1563.
175. BD Meade, A Deforest, KM Edwards, et al. (1995) Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96(3 Pt 2), 570-575.
176. F Lynn, GF Reed and BD Meade (1997) A comparison of enzyme immunoassays used to measure serum antibodies to components of Bordetella pertussis. Dev Biol Stand 89 197-204.
177. F Lynn, GF Reed and BD Meade (1996) Collaborative study for the evaluation of enzyme-linked immunosorbent assays used to measure human antibodies to Bordetella pertussis antigens. Clin Diagn Lab Immunol 3(6), 689-700.
178. E Reizenstein, HO Hallander, WC Blackwelder, et al. (1995) Comparison of five calculation modes for antibody ELISA procedures using pertussis serology as a model. J Immunol Methods 183(2), 279-290.
179. CD Marchant, AM Loughlin, SM Lett, et al. (1994) Pertussis in Massachusetts, 1981–1991: incidence, serologic diagnosis, and vaccine effectiveness. J Infect Dis 169(6), 1297-1305.
180. WK Yih, SM Lett, FN des Vignes, et al. (2000) The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989–1998. J Infect Dis 182(5), 1409-1416.
181. P Strebel, J Nordin, K Edwards, et al. (2001) Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995–1996. J Infect Dis 183(9), 1353-1359.
182. HE de Melker, FG Versteegh, MA Conyn-Van Spaendonck, et al. (2000) Specificity and sensitivity of high levels of immunoglobulin G antibodies against pertussis toxin in a single serum sample for diagnosis of infection with Bordetella pertussis. J Clin Microbiol 38(2), 800-806.
183. HO Hallander (1997) Diagnostic pertussis serology in the recent clinical efficacy studies of acellular vaccines. Dev Biol Stand 89 205-212.
184. T Tiwari, TV Murphy and J Moran (2005) Recommended antimicrobial agents for the treatment and postexposure prophylaxis of pertussis: 2005 CDC Guidelines. MMWR Recomm Rep 54(RR-14), 1-16.
185. SA Halperin, R Bortolussi, JM Langley, et al. (1997) Seven days of erythromycin estolate is as effective as fourteen days for the treatment of Bordetella pertussis infections. Pediatrics 100(1), 65-71.
186. JW Bass, EL Klenk, JB Kotheimer, et al. (1969) Antimicrobial treatment of pertussis. J Pediatr 75(5), 768-781.
187. EL Hewlett (1995) Bordetella species. G Mandell (Eds) Douglas and Bennett's Principles and Practice of Infectious Diseases 4th ed. New York: Churchill Livingstone
188. EA Mortimer Jr and PK Jones (1979) An evaluation of pertussis vaccine. Rev Infect Dis 1(6), 927-934.
189. HC Peter G, NA Halsey, et al. (1997) Report of the Committee on Infectious Diseases 24th ed American Academy of Pedicitrics
190. H Kawai, T Aoyama, A Goto, et al. (1994) Evaluation of pertussis treatment with erythromycin ethylsuccinate and stearate according to age. Kansenshogaku Zasshi 68(11), 1324-1329.
191. T Aoyama, K Sunakawa, S Iwata, et al. (1996) Efficacy of short-term treatment of pertussis with clarithromycin and azithromycin. J Pediatr 129(5), 761-764.
192. SA Halperin, R Bortolussi, JM Langley, et al. (1999) A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics 104(4), e42.
193. R Bortolussi, B Miller, M Ledwith and S Halperin (1995) Clinical course of pertussis in immunized children. Pediatr Infect Dis J 14(10), 870-874.
194. W Kwantes, DH Joynson and WO Williams (1983) Bordetella pertussis isolation in general practice: 1977–79 whooping cough epidemic in West Glamorgan. J Hyg (Lond) 90(2), 149-158.
195. R Henry, D Dorman, J Skinner and C Mellis (1981) Limitations of erythromycin in whooping cough. Med J Aust 2(2), 108-109.
196. JE Hoppe, E Rahimi-Galougahi and G Seibert (1996) In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem. Antimicrob Agents Chemother 40(3), 807-808.
197. JE Hoppe and A Bryskier (1998) In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). Antimicrob Agents Chemother 42(4), 965-966.
198. JM Langley, SA Halperin, FD Boucher and B Smith (2004) Azithromycin is as effective as and better tolerated than erythromycin estolate for the treatment of pertussis. Pediatrics 114(1), e96-e101.
199. Prevention CfDC (2000) Hypertrophic pyloric stenosis in infants following pertussis prophylasis with erythromycin Knoxville, Tennessee. JAMA 283 471-472.
200. MA Honein, LJ Paulozzi, IM Himelright, et al. (1999) Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromcyin: a case review and cohort study. Lancet 354(9196), 2101-2105.
201. CDC (1995) Erythromycin-resistant Bordetella pertussis Yuma County, Arizona, May-October, 1994. JAMA 273 13-14.
202. KA Gordon, J Fusco, DJ Biedenbach, et al. (2001) Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: report from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 45(12), 3599-3600.
203. EK Korgenski and JA Daly (1997) Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States. J Clin Microbiol 35(11), 2989-2991.
204. JM Bartkus, BA Juni, K Ehresmann, et al. (2003) Identification of a mutation associated with erythromycin resistance in Bordetella pertussis: implications for surveillance of antimicrobial resistance. J Clin Microbiol 41(3), 1167-1172.
205. Bartkus J, Juni BA, Ehresman K. Proposed mechanism of erythromycin resistance in Bordetella pertussi [abst C1–1817]. Paper presented at: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2001; Chicago, IL.
206. AS Beneson (1995) Control of Communicable Disease Manual 16th ed. Washington, DC: American Public Health Association
207. DJ Weber and WA Rutala (1994) Management of healthcare workers exposed to pertussis. Infect Control Hosp Epidemiol 15(6), 411-415.
208. SW Decker MD (1996) Nosocomial Diseases of health care workers spread by airborne or contact route (other than tuberculosis) Baltimore: Williams & Wilkins
209. CH Wirsing von Konig, HJ Schmitt, H Bogaerts, et al. (1997) Factors influencing the analysis of secondary prevention of pertussis. Dev Biol Stand 89 175-179.
210. G De Serres, N Boulianne and B Duval (1995) Field effectiveness of erythromycin prophylaxis to prevent pertussis within families. Pediatr Infect Dis J 14(11), 969-975.
211. PE Fine and JA Clarkson (1982) The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1(8273), 666-669.
212. KM Farizo, SL Cochi, ER Zell, et al. (1992) Epidemiological features of pertussis in the United States, 1980–1989. Clin Infect Dis 14(3), 708-719.
213. D Guris, PM Strebel, B Bardenheier, et al. (1999) Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990–1996. Clin Infect Dis 28(6), 1230-1237.
214. JD Cherry (1984) The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr Probl Pediatr 14(2), 1-78.
215. K Kanai (1980) Japan's experience in pertussis epidemiology and vaccination in the past thirty years. Jpn J Med Sci Biol 33(3), 107-143.
216. JD Cherry, LJ Baraff and E Hewlett (1989) The past, present, and future of pertussis. The role of adults in epidemiology and future control. West J Med 150(3), 319-328.
217. JD Cherry (1998) Pertussis in adults. Ann Intern Med 128(1), 64-66.
218. P Luttinger (1916) The epidemiology of pertussis. Am J Dis Child 12 290-315.
219. A Friedlander (1925) Whooping cough. Pediatrics 11 128-147.
220. Pertussis—United States, 2001–2003. MMWR Morb Mortal Wkly Rep 54(50), 1283-1286.
221. HJ Lambert (1965) Epidemiology of a small pertussis outbreak in Kent County, Michigan. Public Health Rep 80 365-369.
222. JD Cherry, T Beer, SA Chartrand, et al. (1995) Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 20(5), 1271-1274.
223. CC Linnemann Jr, JW Bass and MH Smith (1968) The carrier state in pertussis. Am J Epidemiol 88(3), 422-427.
224. HP Lambert (1986) The carrier state: Bordetella pertussis. J Antimicrob Chemother 18(Suppl A), 13-16.
225. S Rosenthal, P Strebel, P Cassiday, et al. (1995) Pertussis infection among adults during the 1993 outbreak in Chicago. J Infect Dis 171(6), 1650-1652.
226. CD Christie, ML Marx, CD Marchant and SF Reising (1994) The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children. N Engl J Med 331(1), 16-21.
227. Resurgence of pertussis—United States, 1993. MMWR Morb Mortal Wkly Rep 42(49), 952-953, 959–960.
228. Pertussis outbreak—Vermont, 1996. MMWR Morb Mortal Wkly Rep 46(35), 822-826.
229. KM Edwards, MD Decker, NA Halsey, et al. (1991) Differences in antibody response to whole-cell pertussis vaccines. Pediatrics 88(5), 1019-1023.
230. KM Edwards and MD Decker (1996) Acellular pertussis vaccines for infants. N Engl J Med 334(6), 391-392.
231. K Stehr, JD Cherry, U Heininger, et al. (1998) A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics 101(1 Pt 1), 1-11.
232. L Gustafsson, HO Hallander, P Olin, et al. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 334(6), 349-355.
233. D Greco, S Salmaso, P Mastrantonio, et al. (1996) A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med 334(6), 341-348.
234. Pertussis—United States, January 1992-June 1995. MMWR Morb Mortal Wkly Rep 44(28), 525-529.
235. SF Davis, PM Strebel, SL Cochi, et al. (1992) Pertussis surveillance—United States, 1989–1991. MMWR CDC Surveill Summ 41(8), 11-19.
236. Q He, MK Viljanen, S Nikkari, et al. (1994) Outcomes of Bordetella pertussis infection in different age groups of an immunized population. J Infect Dis 170(4), 873-877.
237. RJ Biellik, PA Patriarca, JR Mullen, et al. (1988) Risk factors for community- and household-acquired pertussis during a large-scale outbreak in central Wisconsin. J Infect Dis 157(6), 1134-1141.
238. CA Mink, NM Sirota and S Nugent (1994) Outbreak of pertussis in a fully immunized adolescent and adult population. Arch Pediatr Adolesc Med 148(2), 153-157.
239. School-associated pertussis outbreak—Yavapai County, Arizona, September 2002–February 2003. MMWR Morb Mortal Wkly Rep 53(10), 216-219.
240. JP Davis (2005) Clinical and economic effects of pertussis outbreaks. Pediatr Infect Dis J 24(6 Suppl), S109-S116.
241. E Elliott, P McIntyre, G Ridley, et al. (2004) National study of infants hospitalized with pertussis in the acellular vaccine era. Pediatr Infect Dis J 23(3), 246-252.
242. PW Robertson, H Goldberg, BH Jarvie, et al. (1987) Bordetella pertussis infection: a cause of persistent cough in adults. Med J Aust 146(10), 522-525.
243. SW Wright, KM Edwards, MD Decker and MH Zeldin (1995) Pertussis infection in adults with persistent cough. JAMA 273(13), 1044-1046.
244. ME Nennig, HR Shinefield, KM Edwards, et al. (1996) Prevalence and incidence of adult pertussis in an urban population. JAMA 275(21), 1672-1674.
245. M Campins-Marti, HK Cheng, K Forsyth, et al. (2001) Recommendations are needed for adolescent and adult pertussis immunisation: rationale and strategies for consideration. Vaccine 20(5–6), 641-646.
246. GM Lee, S Lett, S Schauer, et al. (2004) Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39(11), 1572-1580.
247. KW Purdy, JW Hay, MF Botteman and JI Ward (2004) Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis 39(1), 20-28.
248. A Van Rie and HW Hethcote (2004) Adolescent and adult pertussis vaccination: computer simulations of five new strategies. Vaccine 22(23–24), 3154-3165.
249. Global Programme on Vaccines Paper presented at: State of the World's Vaccines and Immunization. World Health Organization, 1996; New York
250. NS Crowcroft, C Stein, P Duclos and M Birmingham (2003) How best to estimate the global burden of pertussis. Lancet Infect Dis 3(7), 413-418.
251. J Van Savage, MD Decker, KM Edwards, et al. (1990) Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 161(3), 487-492.
252. CM Healy, FM Munoz, MA Rench, et al. (2004) Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 190(2), 335-340.
253. JA Lichty, B Slavin and WL Bradford (1938) An attempt to increase resistance to pertussis in newborn infants by immunizing their mothers during pregnancy. J Clin Invest 17(5), 613-621.
254. Pertussis antibodies in pregnant women (1942) Protective, agglutinating and complement fixing antibodies before and after vaccination. Am J Dis Child 64 608-617.
255. P Cohen and S Scadron (1943) The Placental transmission of protective antibodies against whooping cough by inoculation of the pregnant mother. JAMA 121 656-662.
256. P Kendrick, M Thompson and G Eldering (1946) Immunity response of mothers and babies to injections of pertussis vaccine during pregnancy. Am J Dis Child 70 25-28.
257. JA Englund, EL Anderson, GF Reed, et al. (1995) The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96(3 Pt 2), 580-584.
258. S Elahi, RM Buchanan, LA Babiuk and V Gerdts (2006) Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 74(5), 2619-2627.
259. W Bradford (1935) Use of convalescent blood in whooping cough. Am J Dis Child 50 918-928.
260. RC Balagtas, KE Nelson, S Levin and SP Gotoff (1971) Treatment of pertussis with pertussis immune globulin. J Pediatr 79(2), 203-208.
261. D Morris and JC McDonald (1957) Failure of hyperimmune gamma globulin to prevent whooping cough. Arch Dis Child 32(163), 236-239.
262. M Granstrom, AM Olinder-Nielsen, P Holmblad, et al. (1991) Specific immunoglobulin for treatment of whooping cough. Lancet 338(8777), 1230-1233.
263. SA Halperin, W Vaudry, FD Boucher, K Mackintosh, TB Waggener and B Smith (2007 Jan) Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet. Pediatric Investigators Collaborative Network on Infections in Canada. Pediatr Infect Dis J 26(1), 79-81.
264. T Madsen (1933) Vaccination against whooping cough. JAMA 101 187-188.
265. P Kendrick, G Eldering and M Dixon (1947) Mouse protection tests in the study of pertussis vaccine: a comparative series using intrcerebral route for challenge. Am J Public Health 37 803-810.
266. G Eldering (1971) Symposium on pertussis immunization, in honor of Dr. Pearl L. Kendrick in her eightietn year: historical notes on pertussis immunization. Health Lab Sci 8(4), 200-205.
267. Vaccination against whooping-cough; relation between protection in children and results of laboratory tests; a report to the Whooping-cough Immunization Committee of the Medical Research Council and to the medical officers of health for Cardiff, Leeds, Leyton, Manchester, Middlesex, Oxford, Poole, Tottenham, Walthamstow, and Wembley. BMJ (4990), 454-462.
268. Y Sato, M Kimura and H Fukumi (1984) Development of a pertussis component vaccine in Japan. Lancet 1(8369), 122-126.
269. M Kimura and N Hikino (1985) Results with a new DTP vaccine in Japan. Dev Biol Stand 61 545-561.
270. GR Noble, RH Bernier, EC Esber, et al. (1987) Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists. JAMA 257(10), 1351-1356.
271. T Aoyama, Y Murase, T Gonda and T Iwata (1988) Type-specific efficacy of acellular pertussis vaccine. Am J Dis Child 142(1), 40-42.
272. M Kimura and H Kuno-Sakai (1990) Current epidemiology of pertussis in Japan. Pediatr Infect Dis J 9(10), 705-709.
273. M Kimura (1991) Japanese clinical experiences with acellular pertussis vaccines. Dev Biol Stand 73 5-9.
274. H Kuno-Sakai and M Kimura (2004) Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization. Pediatr Int 46(6), 650-655.
275. KM Edwards, BD Meade, MD Decker, et al. (1995) Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 96(3 Pt 2), 548-557.
276. N Guiso, C Capiau, G Carletti, et al. (1999) Intranasal murine model of Bordetella pertussis infection. I. Prediction of protection in human infants by acellular vaccines. Vaccine 17(19), 2366-2376.
277. K Edwards, M Decker and EA Mortimer (1999) Pertussis vaccine. S Plotkin, EA Mortimer, Jr, WA Orenstein (Eds) Vaccines 3rd ed Philadelphia: WB Saunders 293-344.
278. DP Greenberg, LK Pickering, SD Senders, et al. (2002) Interchangeability of 2 diphtheria-tetanus-acellular pertussis vaccines in infancy. Pediatrics 109(4), 666-672.
279. AR Hinman and JP Koplan (1984) Pertussis and pertussis vaccine. Reanalysis of benefits, risks, and costs. JAMA 251(23), 3109-3113.
280. DL Miller, R Alderslade and EM Ross (1982) Whooping cough and whooping cough vaccine: the risks and benefits debate. Epidemiol Rev 4 1-24.
281. P Kendrick and G Eldering (1936) Progress report on pertussis immunization. Am J Public Health 26 8-12.
282. L Sauer (1939) Whooping Cough: new phases of the work of immunizations and prophylaxis. JAMA 112 305-308.
283. JD Baker, SA Halperin, K Edwards, et al. (1992) Antibody response to Bordetella pertussis antigens after immunization with American and Canadian whole-cell vaccines. J Pediatr 121(4), 523-527.
284. MC Steinhoff, GF Reed, MD Decker, et al. (1995) A randomized comparison of reactogenicity and immunogenicity of two whole-cell pertussis vaccines. Pediatrics 96(3 Pt 2), 567-570.
285. J Doull, G Shibley and J McClelland (1936) Active immunization against whooping cough: interim report of the Cleveland experience. Am J Public Health 26 1097-1105.
286. W Sako (1947) Studies on pertussis immunization. J Pediatr 30 29-40.
287. Vaccination against whooping-cough the final report to the Whooping-Cough Immunization Committee of the Medical Research Council and to the medical officers of health for Battersea and Wandsworth, Bradford, Liverpool, and Newcastle. BMJ 46(5128), 994-1000.
288. HJ Schmitt, CH von Konig, A Neiss, et al. (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275(1), 37-41.
289. JG Liese, CK Meschievitz, E Harzer, et al. (1997) Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr Infect Dis J 16(11), 1038-1044.
290. Lederle Laboratories (1997) ACEL-MUNE product labeling Montvale, NJ: Medical Economics Company
291. F Simondon, MP Preziosi, A Yam, et al. (1997) A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15(15), 1606-1612.
292. ME Ramsay, CP Farrington and E Miller (1993) Age-specific efficacy of pertussis vaccine during epidemic and non-epidemic periods. Epidemiol Infect 111(1), 41-48.
293. JM White, CK Fairley, D Owen, et al. (1996) The effect of an accelerated immunisation schedule on pertussis in England and Wales. Commun Dis Rep CDR Rev 6(6), R86-R91.
294. E Miller, LA Ashworth, K Redhead, et al. (1997) Effect of schedule on reactogenicity and antibody persistence of acellular and whole-cell pertussis vaccines: value of laboratory tests as predictors of clinical performance. Vaccine 15(1), 51-60.
295. H Lautrop and OS Mikkelsen (1969) [The effect of prophylactic whooping-cough vaccination. An attempt at an evaluation based on experiences in Denmark]. Ugeskr Laeger 131(17), 735-741.
296. RW Sutter and SL Cochi (1992) Pertussis hospitalizations and mortality in the United States, 1985–1988. Evaluation of the completeness of national reporting. JAMA 267(3), 386-391.
297. C Dauer (1943) Reported whooping cough morbidity and mortality in the United States. Public Health Rep 58 661-676.
298. M Kimura and H Kuno-Sakai (1988) Immunization system in Japan: its history and present situation. Acta Paediatr Jpn 30(2), 109-126.
299. Stuart-Harris Experiences of pertussis in the United Kingdom. Paper presented at: International Symposium on Pertussis, 1979; Bethesda, MD.
300. V Romanus, R Jonsell and SO Bergquist (1987) Pertussis in Sweden after the cessation of general immunization in 1979. Pediatr Infect Dis J 6(4), 364-371.
301. J Storsaeter and P Olin (1992) Relative efficacy of two acellular pertussis vaccines during three years of passive surveillance. Vaccine 10(3), 142-144.
302. J Taranger, B Trollfors, E Bergfors, et al. (2001) Immunologic and epidemiologic experience of vaccination with a monocomponent pertussis toxoid vaccine. Pediatrics 108(6), E115.
303. S Baron, E Njamkepo, E Grimprel, et al. (1998) Epidemiology of pertussis in French hospitals in 1993 and 1994: thirty years after a routine use of vaccination. Pediatr Infect Dis J 17(5), 412-418.
304. R Pollard (1980) Relation between vaccination and notification rates for whooping cough in England and Wales. Lancet 1(8179), 1180-1182.
305. IM Onorato, SG Wassilak and B Meade (1992) Efficacy of whole-cell pertussis vaccine in preschool children in the United States. JAMA 267(20), 2745-2749.
306. CK Vesselinova-Jenkins, RG Newcombe, OP Gray, et al. (1978) The effects of immunisation upon the natural history of pertussis. A family study in the Cardiff area. J Epidemiol Community Health 32(3), 194-199.
307. PR Grob, MJ Crowder and JF Robbins (1981) Effect of vaccination on severity and dissemination of whooping cough. BMJ (Clin Res Ed) 282(6280), 1925-1928.
308. MP Preziosi and ME Halloran (2003) Effects of pertussis vaccination on disease: vaccine efficacy in reducing clinical severity. Clin Infect Dis 37(6), 772-779.
309. MP Preziosi and ME Halloran (2003) Effects of pertussis vaccination on transmission: vaccine efficacy for infectiousness. Vaccine 21(17–18), 1853-1861.
310. B Cvjetanovic, B Grab and K Uemura (1978) Diphtheria and whooping cough: diseases affecting a paticular age group. Bull World Health Organ 56(Suppl 1), 103-133.
311. JP Fox, L Elveback, W Scott, et al. (1995) Herd immunity: basic concept and relevance to public health immunization practices. 1971. Am J Epidemiol 141(3), 187-197; discussion 185–186.
312. DR Feikin, DC Lezotte, RF Hamman, et al. (2000) Individual and community risks of measles and pertussis associated with personal exemptions to immunization. JAMA 284(24), 3145-3150.
313. D Jenkinson (1988) Duration of effectiveness of pertussis vaccine: evidence from a 10 year community study. BMJ (Clin Res Ed) 296(6622), 612-614.
314. PE Fine and JA Clarkson (1987) Reflections on the efficacy of pertussis vaccines. Rev Infect Dis 9(5), 866-883.
315. E Weiss and P Kendrick (1943) The effectiveness of pertussis vaccine: an application of Sargent and Merrell's method of measurement. Am J Hyg 38 306-309.
316. CP Howson and HV Fineberg (1992) Adverse events following pertussis and rubella vaccines. Summary of a report of the Institute of Medicine. JAMA 267(3), 392-396.
317. CJ Howe Stratton and RB Johnston (1994) DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis Washington, DC: National Academy Press
318. Howson CP, Howe BJ, Fineberg HV. AdverseEffects of Pertussis and Rubella Vaccines: Report of the committee to review the Adverse Consequences of Pertussis and Rubella Vaccines Institute of Medicine. Paper presented at: Washington, DC, 1991.
319. E Mortimer (1994) Pertussis. S Plotkin, E Mortimer (Eds) Vaccines 2nd ed. Philadelphia: WB Saunders
320. Diphtheria, tetanus, and pertussis recommendations for vaccine use and other preventive measures. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 40(RR-10), 1-28.
321. M Cadoz, F Arminjon and MJ Quentin-Millet (1986) Safety and immunogenicity of Merieux acellular pertussis in adult volunteers. In transcript of the Workshop on Acellular Pertussis Vaccines Washington, DC: U.S. Department of Health and Human Services 131-134.
322. CL Cody, LJ Baraff, JD Cherry, et al. (1981) Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68(5), 650-660.
323. MD Decker, KM Edwards, MC Steinhoff, et al. (1995) Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 96(3 Pt 2), 557-566.
324. LJ Baraff, CL Cody and JD Cherry (1984) DTP-associated reactions: an analysis by injection site, manufacturer, prior reactions, and dose. Pediatrics 73(1), 31-36.
325. ME Pichichero, C Christy, MD Decker, et al. (1995) Defining the key parameters for comparing reactions among acellular and whole-cell pertussis vaccines. Pediatrics 96(3 Pt 2), 588-592.
326. MA Deloria, WC Blackwelder, MD Decker, et al. (1995) Association of reactions after consecutive acellular or whole-cell pertussis vaccine immunizations. Pediatrics 96(3 Pt 2), 592-594.
327. DG Hirtz, KB Nelson and JH Ellenberg (1983) Seizures following childhood immunizations. J Pediatr 102(1), 14-18.
328. AM Walker, H Jick, DR Perera, et al. (1988) Neurologic events following diphtheria-tetanus-pertussis immunization. Pediatrics 81(3), 345-349.
329. MR Griffin, WA Ray, EA Mortimer, et al. (1990) Risk of seizures and encephalopathy after immunization with the diphtheria-tetanus-pertussis vaccine. JAMA 263(12), 1641-1645.
330. HC Stetler, WA Orenstein, KJ Bart, et al. (1985) History of convulsions and use of pertussis vaccine. J Pediatr 107(2), 175-179.
331. M Bellman and E Ross (1985) Pertussis immunizations and fits. E Ross, E Reynolds (Eds) Peadiatric Perspectives on Epilepsy New York: John Wiley
332. JR Livengood, JR Mullen, JW White, et al. (1989) Family history of convulsions and use of pertussis vaccine. J Pediatr 115(4), 527-531.
333. Center for Biologics Evaluation and Research (U.S.). Proceedings of the Sixth International Symposium on Pertussis, Jack Masur Auditorium, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland, September 26–28, 1990. Bethesda, Md.: Dept. of Health and Human Services, United States Public Health Service, Food and Drug Administration; 1990.
334. JH Ellenberg, DG Hirtz and KB Nelson (1986) Do seizures in children cause intellectual deterioration. N Engl J Med 314(17), 1085-1088.
335. WD Shields, C Nielsen, D Buch, et al. (1988) Relationship of pertussis immunization to the onset of neurologic disorders: a retrospective epidemiologic study. J Pediatr 113(5), 801-805.
336. MM Braun, G Terracciano, ME Salive, et al. (1998) Report of a US public health service workshop on hypotonic-hyporesponsive episode (HHE) after pertussis immunization. Pediatrics 102(5), E52.
337. DC Miller, MJ Wadsworth and EM Ross (1989) Pertussis vaccine and severe acute neurological illnesses. Response to a recent review by members of the NCES team. Vaccine 7(6), 487-489.
338. MH Bellman, EM Ross and DL Miller (1983) Infantile spasms and pertussis immunisation. Lancet 1(8332), 1031-1034.
339. Safety of pertussis vaccine. Lancet 335(8690), 655-656.
340. D Miller, N Madge, J Diamond, J Wadsworth and E Ross (1993) Pertussis immunisation and serious acute neurological illnesses in children. BMJ 307(6913), 1171-1176.
341. AH Griffith (1989) Pertussis vaccines and permanent brain damage. Vaccine 7(6), 489-490.
342. C Bowie (1990) Lessons from the pertussis vaccine court trial. Lancet 335(8686), 397-399.
343. JB Stephenson (1988) A neurologist looks at neurological disease temporally related to DTP immunization. Tokai J Exp Clin Med 13(Suppl), 157-164.
344. A Leviton (1989) Neurologic sequelae of pertussis immunization–1989. J Child Neurol 4(4), 311-314.
345. Riikonen R, Donner M. Incidence and aetiology of infantile spasms from 1960 to 1976: a population study in Finland. Dev Med Child Neurol 21(3):333–343, 1979.
346. R Riikonen and M Donner (1979) Incidence and aetiology of infantile spasms from 1960 to 1976: a population study in Finland. Dev Med Child Neurol 21(3), 333-343.
347. JG Millichap (1987) Etiology and treatment of infantile spasms: current concepts, including the role of DPT immunization. Acta Paediatr Jpn 29(1), 54-60.
348. JC Melchior (1977) Infantile spasms and early immunization against whooping cough. Danish survey from 1970 to 1975. Arch Dis Child 52(2), 134-137.
349. Y Fukuyama, N Tomori and M Sugitate (1977) Critical evaluation of the role of immunization as an etiological factor of infantile spasms. Neuropadiatrie 8(3), 224-237.
350. CT Lombroso (1983) A prospective study of infantile spasms: clinical and therapeutic correlations. Epilepsia 24(2), 135-158.
351. B Guyer, JA Martin, MF MacDorman, et al. (1997) Annual summary of vital statistics—1996. Pediatrics 100(6), 905-918.
352. RH Bernier, JA Frank Jr, TJ Dondero Jr and P Turner (1982) Diphtheria-tetanus toxoids-pertussis vaccination and sudden infant deaths in Tennessee. J Pediatr 101(3), 419-421.
353. LJ Baraff, WJ Ablon and RC Weiss (1983) Possible temporal association between diphtheria-tetanus toxoid-pertussis vaccination and sudden infant death syndrome. Pediatr Infect Dis 2(1), 7-11.
354. W Torch (1982) Diphtheria-pertussis-tetanus (DPT) immunization: a potential cause of sudden infant death syndrome (SIDS). J Pediatr 101 169-170.
355. W Torch (1986) Characteristics of diphtheria-pertussis-tetanus (DPT) postvaccinal deaths and DPT-caused suddent infant death syndrome (SIDS): a review. Neurology 36(suppl 1), 148.
356. B Nickerson and B Robison (1985) How many sudden infant death syndrome victims were recently immunized? Western Soc Pediatr Res Clin Res 33 121A.
357. EM Taylor and JL Emergy (1982) Immunization and cot deaths. Lancet 2(8300), 721.
358. HJ Hoffman, JC Hunter, K Damus, et al. (1987) Diphtheria-tetanus-pertussis immunization and sudden infant death: results of the National Institute of Child Health and Human Development Cooperative Epidemiological Study of Sudden Infant Death Syndrome risk factors. Pediatrics 79(4), 598-611.
359. MH Bouvier-Colle, A Flahaut, A Messiah, et al. (1989) Sudden infant death and immunization: an extensive epidemiological approach to the problem in France—winter 1986. Int J Epidemiol 18(1), 121-126.
360. MR Griffin, WA Ray, JR Livengood and W Schaffner (1988) Risk of sudden infant death syndrome after immunization with the diphtheria-tetanus-pertussis vaccine. N Engl J Med 319(10), 618-623.
361. Geraghty K, Presentation to the Immunization Practices Advisory Committee, Centers for Disease Control; October 25, 1985; Atlanta, GA.
362. AM Walker, H Jick, DR Perera, et al. (1987) Diphtheria-tetanus-pertussis immunization and sudden infant death syndrome. Am J Public Health 77(8), 945-951.
363. Solberg DTP immunization, visit to child health center and sudden infant death syndrome (SIDS). Paper presented at: Oslo Health Council, 1985; Norway.
364. G Wennergren, J Milerad, H Lagercrantz, et al. (1987) The epidemiology of sudden infant death syndrome and attacks of lifelessness in Sweden. Acta Paediatr Scand 76(6), 898-906.
365. CP Howson and HV Fineberg (1992) The ricochet of magic bullets: summary of the Institute of Medicine Report, Adverse Effects of Pertussis and Rubella Vaccines. Pediatrics 89(2), 318-324.
366. DM Skowronski, G De Serres, D MacDonald, et al. (2002) The changing age and seasonal profile of pertussis in Canada. J Infect Dis 185(10), 1448-1453.
367. D Ridgway (1998) Disputed claims for pertussis vaccine injuries under the National Vaccine Injury Compensation Program. J Investig Med 46(4), 168-174.
368. KH Mills, A Barnard, J Watkins and K Redhead (1993) Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model. Infect Immun 61(2), 399-410.
369. JW Petersen, P Andersen, PH Ibsen, et al. (1993) Proliferative responses to purified and fractionated Bordetella pertussis antigens in mice immunized with whole-cell pertussis vaccine. Vaccine 11(4), 463-472.
370. JW Petersen, PH Ibsen, K Haslov and I Heron (1992) Proliferative responses and gamma interferon and tumor necrosis factor production by lymphocytes isolated from tracheobroncheal lymph nodes and spleen of mice aerosol infected with Bordetella pertussis. Infect Immun 60(11), 4563-4570.
371. K Redhead, J Watkins, A Barnard and KH Mills (1993) Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect Immun 61(8), 3190-3198.
372. PC Adamson, TC Wu, BD Meade, et al. (1989) Pertussis in a previously immunized child with human immunodeficiency virus infection. J Pediatr 115(4), 589-592.
373. K Bromberg, G Tannis and P Steiner (1991) Detection of Bordetella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect Immun 59(12), 4715-4719.
374. KH Mills, M Ryan, E Ryan and BP Mahon (1998) A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect Immun 66(2), 594-602.
375. AJ Gearing, CR Bird, K Redhead and M Thomas (1989) Human cellular immune responses to Bordetella pertussis infection. FEMS Microbiol Immunol 1(4), 205-211.
376. MT De Magistris, M Romano, S Nuti, et al. (1988) Dissecting human T cell responses against Bordetella species. J Exp Med 168(4), 1351-1362.
377. S Peppoloni, L Nencioni, A Di Tommaso, et al. (1991) Lymphokine secretion and cytotoxic activity of human CD4+ T-cell clones against Bordetella pertussis. Infect Immun 59(10), 3768-3773.
378. JW Petersen, PH Ibsen, MW Bentzon, et al. (1991) The cell mediated and humoral immune response to vaccination with acellular and whole cell pertussis vaccine in adult humans. FEMS Microbiol Immunol 3(5), 279-287.
379. A Podda, L Nencioni, MT De Magistris, et al. (1990) Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G. J Exp Med 172(3), 861-868.
380. CU Meyer, F Zepp, M Decker, M Lee, SJ Chang, J Ward, S Yoder, H Bogaert and KM Edwards (2007 Mar) Cellular immunity in adolescents and adults following acellular pertussis vaccine administration. Clin Vaccine Immunol 14(3), 288-292. Epub 2007 Jan 31.
381. F Zepp, M Knuf, P Habermehl, et al. (1996) Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 64(10), 4078-4084.
382. N Guiso, E Njamkepo, F Vié le Sage, F Zepp, CU Meyer, V Abitbol, N Clyti and S Chevallier (2007 Feb 9) Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 25(8), 1390-1397. Epub 2006 Nov 7
383. CM Ausiello, R Lande, F Urbani, et al. (2000) Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine. J Infect Dis 181(6), 1989-1995.
384. CM Ausiello, R Lande, F Urbani, et al. (1999) Cell-mediated immune responses in four-year-old children after primary immunization with acellular pertussis vaccines. Infect Immun 67(8), 4064-4071.
385. A Cassone, CM Ausiello and F Urbani (1997) Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussi vaccines. Arch Pediatr Adolesc Med 151 282-289.
386. A Cassone, P Mastrantonio and CM Ausiello (2000) Are only antibody levels involved in the protection against pertussis in acellular pertussis vaccine recipients. J Infect Dis 182(5), 1575-1577.
387. NN Tran Minh, Q He, K Edelman, et al. (1999) Cell-mediated immune responses to antigens of Bordetella pertussis and protection against pertussis in school children. Pediatr Infect Dis J 18(4), 366-370.
388. KJ Edelman, Q He, JP Makinen, et al. (2004) Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis 39(2), 179-185.
389. SR Miller JJ and TM Saito (1943) An agglutinative reaction for Haemophilus pertussis, II: its relations to clincial immunity. J Pediatr 22 644-651.
390. P Olin, HO Hallander, L Gustafsson, et al. (2001) How to make sense of pertussis immunogenicity data. Clin Infect Dis 33(Suppl 4), S288-S291.
391. JD Cherry, J Gornbein, U Heininger and K Stehr (1998) A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16(20), 1901-1906.
392. EL Hewlett and SA Halperin (1998) Serological correlates of immunity to Bordetella pertussis. Vaccine 16(20), 1899-1900.
393. GA Poland (1997) Still more questions on pertussis vaccines. Lancet 350(9091), 1564-1565.
394. Pertussis vaccination acellular pertussis vaccine for reinforcing and booster use—supplementary ACIP statement. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 41(RR-1), 1-10.
395. J Storsaeter, P Olin, B Renemar, et al. (1988) Mortality and morbidity from invasive bacterial infections during a clinical trial of acellular pertussis vaccines in Sweden. Pediatr Infect Dis J 7(9), 637-645.
396. S Isomura (1989) License application for pertussis vaccine withdrawn in Sweden. Lancet 1989;I:114. Lancet 1 114.
397. MH Samore and GR Siber (1992) Effect of pertussis toxin on susceptibility of infant rats to Haemophilus influenzae type b. J Infect Dis 165(5), 945-948.
398. SB Black, JD Cherry, HR Shinefield, et al. (1991) Apparent decreased risk of invasive bacterial disease after heterologous childhood immunization. Am J Dis Child 145(7), 746-749.
399. M Davidson, GW Letson, JI Ward, et al. (1991) DTP immunization and susceptibility to infectious diseases. Is there a relationship. Am J Dis Child 145(7), 750-754.
400. LS Joffe, MP Glode, MK Gutierrez, et al. (1992) Diphtheria-tetanus toxoids-pertussis vaccination does not increase the risk of hospitalization with an infectious illness. Pediatr Infect Dis J 11(9), 730-735.
401. M Kimura and H Kuno-Sakai (1988) Acellular pertussis vaccines and fatal infections. Lancet 1(8590), 881-882.
402. WC Blackwelder, J Storsaeter, P Olin and HO Hallander (1991) Acellular pertussis vaccines. Efficacy and evaluation of clinical case definitions. Am J Dis Child 145(11), 1285-1289.
403. J Storsaeter, H Hallander, CP Farrington, et al. (1990) Secondary analyses of the efficacy of two acellular pertussis vaccines evaluated in a Swedish phase III trial. Vaccine 8(5), 457-461.
404. Olin P, Storsaeter J. Vaccine efficacy. In a Clinical Trial of Accellular Pertussis Vaccines in Sweden, Techinical Report. Paper presented at: National Bacteriological Laboratory, 1988; Stockholm, Sweden.
405. World Health Organistion WHO Meeting on Case Definition of Pertussis. Paper presented at: Who Meeting on Case Definition of Pertussis; January 10–11, 1991; Geneva WHO, 1:4–5.
406. Gustafsson L, Hallander H, Olin P. Efficacy Trial of Acellular Pertussis Vaccines: Techinical Report Trial I, with Results of Preplanned Analysis of Safety, Efficacy and Immunogenicity. Paper presented at: Swedish Institute for Infectious Diseases Control, 1995; Stockholm, Sweden.
407. HO Hallander, J Storsaeter and R Mollby (1991) Evaluation of serology and nasopharyngeal cultures for diagnosis of pertussis in a vaccine efficacy trial. J Infect Dis 163(5), 1046-1054.
408. J Taranger, B Trollfors, T Lagergard, et al. (1997) Unchanged efficacy of a pertussis toxoid vaccine throughout the two years after the third vaccination of infants. Pediatr Infect Dis J 16(2), 180-184.
409. U Heininger, JD Cherry, T Eckhardt, et al. (1993) Clinical and laboratory diagnosis of pertussis in the regions of a large vaccine efficacy trial in Germany. Pediatr Infect Dis J 12(6), 504-509.
410. KM Edwards and MD Decker (1997) Comparison of serological results in the NIAID Multicenter Acellular Pertussis Trial with recent efficacy trials. Dev Biol Stand 89 265-273.
411. S Salmaso, A Anemona, P Mastrantonio, et al. (1998) Long-term efficacy of pertussis vaccines in Italy. PROPER Study Working Group. Dev Biol Stand 95 189-194.
412. S Salmaso, P Mastrantonio, AE Tozzi, et al. (2001) Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics 108(5), E81.
413. P Olin, F Rasmussen, L Gustafsson, et al. (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350(9091), 1569-1577.
414. SA Plotkin and M Cadoz (1997) Acellular vaccine efficacy trials. Pediatr Infect Dis J 16(9), 913-914.
415. B Trollfors, J Taranger, T Lagergard, et al. (1995) A placebo-controlled trial of a pertussis-toxoid vaccine. N Engl J Med 333(16), 1045-1050.
416. B Trollfors, J Taranger, T Lagergard, et al. (1997) Efficacy of a monocomponent pertussis toxoid vaccine after household exposure to pertussis. J Pediatr 130(4), 532-536.
417. J Taranger, B Trollfors, E Bergfors, et al. (2001) Mass vaccination of children with pertussis toxoid–decreased incidence in both vaccinated and nonvaccinated persons. Clin Infect Dis 33(7), 1004-1010.
418. U Heininger, JD Cherry, K Stehr, et al. (1998) Comparative Efficacy of the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine and Lederle whole-cell component DTP vaccine in German children after household exposure. Pertussis Vaccine Study Group. Pediatrics 102(3 Pt 1), 546-553.
419. JD Cherry, U Heininger, K Stehr and P Christenson (1998) The effect of investigator compliance (observer bias) on calculated efficacy in a pertussis vaccine trial. Pediatrics 102(4 Pt 1), 909-912.
420. S Lugauer, U Heininger, JD Cherry and K Stehr (2002) Long-term clinical effectiveness of an acellular pertussis component vaccine and a whole cell pertussis component vaccine. Eur J Pediatr 161(3), 142-146.
421. F Simondon (1997) Senegal pertussis trial. Dev Biol Stand 89 63-66.
422. SA Plotkin and M Cadoz (1997) The acellular pertussis vaccine trials: an interpretation. Pediatr Infect Dis J 16(5), 508-517; discussion 517–509.
423. JD Cherry (1997) Comparative efficacy of acellular pertussis vaccines:an analysis of recent trials. Pediatr Infect Dis J 16(4 suppl), S90–S96.
424. Gustafsson L, Hallander H, Olin P. Pertussis Surveillance in Sweden: progress report Oct 1997–september 2004 with executive summary. Seven year report: Swedish Institute for Infectious Disease Contrl (SMI); June 16, 2005.
425. Olin P, Gustafsson L, Rasmussen F. Efficacy Trial of Acellular Pertussis Vaccines: Technical Report Trial II, with Results of Preplanned Analysis of Efficacy and Immunogenicity and Safety, 1997. Stockholm, Sweden: 1997.
426. L Gustafsson, L Hessel, J Storsaeter and P Olin (2006) Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 118(3), 978-984.
427. M Kimura and H Kuno-Sakai (1988) Pertussis vaccines in Japan. Acta Paediatr Jpn 30(2), 143-153.
428. M Kimura and H Kuno-Sakai (1988) Epidemiology of pertussis in Japan. Tokai J Exp Clin Med 13(Suppl:1–7),
429. Y Sato and H Sato (1988) Further characterization of Japanese acellular pertussis vaccine prepared in 1988 by 6 Japanese manufacturers. Tokai J Exp Clin Med 13(Suppl), 79-88.
430. A Ginnaga, K Morokuma, K Aihara, et al. (1988) Characterization and clinical study on the acellular pertussis vaccine produced by a combination of column purified pertussis toxin and filamentous hemagglutinin. Tokai J Exp Clin Med 13(Suppl), 59-69.
431. M Kimura and H Kuno-Sakai (1990) Developments in pertussis immunisation in Japan. Lancet 336(8706), 30-32.
432. M Pittman (1991) History of the development of pertussis vaccine. Dev Biol Stand 73 13-29.
433. T Aoyama, Y Murase, M Kato, et al. (1989) Efficacy and immunogenicity of acellular pertussis vaccine by manufacturer and patient age. Am J Dis Child 143(6), 655-659.
434. S Isomura, S Suzuki and Y Sato (1985) Clinical efficacy of the Japanese acellular pertussis vaccine after intrafamiliar exposure to pertussis patients. Dev Biol Stand 61 531-537.
435. EA Mortimer Jr, M Kimura, JD Cherry, et al. (1990) Protective efficacy of the Takeda acellular pertussis vaccine combined with diphtheria and tetanus toxoids following household exposure of Japanese children. Am J Dis Child 144(8), 899-904.
436. JD Cherry, EA Mortimer, JG Hackell and JV Scott (1991) Clinical trials in the United States and Japan with the Lederle-Takeda and Takeda acellular pertussis-diphtheria-tetanus (APDT) vaccines. The Multicenter APDT Vaccine Study Groups. Dev Biol Stand 73 51-58.
437. H Kuno-Sakai, M Kimura, K Ozaki, et al. (1988) Japanese clinical trials with Takeda acellular pertussis vaccine. Tokai J Exp Clin Med 13(Suppl), 15-19.
438. CM Morgan, DA Blumberg, JD Cherry, et al. (1990) Comparison of acellular and whole-cell pertussis-component DTP vaccines. A multicenter double-blind study in 4- to 6-year-old children. Am J Dis Child 144(1), 41-45.
439. M Glode, L Joffe, K Reisinger, et al. (1992) Safety and immunogenicity of acellular pertussis vaccine combined with diphtheria and tetanus toxoids in 17- to 24-month-old children. Pediatr Infect Dis J 11(7), 530-535.
440. DA Blumberg, CM Mink, JD Cherry, et al. (1990) Comparison of an acellular pertussis-component diphtheria-tetanus-pertussis (DTP) vaccine with a whole-cell pertussis-component DTP vaccine in 17- to 24-month-old children, with measurement of 69-kilodalton outer membrane protein antibody. J Pediatr 117(1 Pt 1), 46-51.
441. H Kamiya, R Nii, T Matsuda, et al. (1992) Immunogenicity and reactogenicity of Takeda acellular pertussis-component diphtheria-tetanus-pertussis vaccine in 2- and 3-month-old children in Japan. Am J Dis Child 146(10), 1141-1147.
442. DA Blumberg, CM Mink, JD Cherry, et al. (1991) Comparison of acellular and whole-cell pertussis-component diphtheria-tetanus-pertussis vaccines in infants. The APDT Vaccine Study Group. J Pediatr 119(2), 194-204.
443. B Watson, A Cawein, BL McKee and JG Hackell (1992) Safety and immunogenicity of acellular pertussis vaccine, combined with diphtheria and tetanus as the Japanese commercial Takeda vaccine, compared with the Takeda acellular pertussis component combined with Lederle's diphtheria and tetanus toxoids in two-, four- and six-month-old infants. Pediatr Infect Dis J 11(11), 930-935.
444. Pertussis vaccination acellular pertussis vaccine for the forth & fifth doses of the DTP series:update to supplementary. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR 41(RR-15), 1-5.
445. P Juretzko, R von Kries, M Hermann, et al. (2002) Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis 35(2), 162-167.
446. KM Edwards and DT Karzon (1990) Pertussis vaccines. Pediatr Clin North Am 37(3), 549-566.
447. K Lewis, JD Cherry, HJ Holroyd, et al. (1986) A double-blind study comparing an acellular pertussis-component DTP vaccine with a whole-cell pertussis-component DTP vaccine in 18-month-old children. Am J Dis Child 140(9), 872-876.
448. KM Edwards, E Lawrence and PF Wright (1986) Diphtheria, tetanus, and pertussis vaccine. A comparison of the immune response and adverse reactions to conventional and acellular pertussis components. Am J Dis Child 140(9), 867-871.
449. KM Edwards, RB Bradley, MD Decker, et al. (1989) Evaluation of a new highly purified pertussis vaccine in infants and children. J Infect Dis 160(5), 832-837.
450. ME Pichichero, JT Badgett, GC Rodgers Jr, et al. (1987) Acellular pertussis vaccine: immunogenicity and safety of an acellular pertussis vs. a whole cell pertussis vaccine combined with diphtheria and tetanus toxoids as a booster in 18- to 24-month old children. Pediatr Infect Dis J 6(4), 352-363.
451. EL Anderson, RB Belshe and J Bartram (1988) Differences in reactogenicity and antigenicity of acellular and standard pertussis vaccines combined with diphtheria and tetanus in infants. J Infect Dis 157(4), 731-737.
452. K Edwards and MD Decker (2004) Pertussis vaccine. SA Plotkin, WA Orenstein (Eds) Vaccines 4th ed. Philadelphia, PA: W.B. Saunders
453. ML Ciofi degli Atti and P Olin (1997) Severe adverse events in the Italian and Stockholm I pertussis vaccine clinical trials. Dev Biol Stand 89 77-81.
454. H Kuno-Sakai and M Kimura (1997) Epidemiology of pertussis and use of acellular pertussis vaccines in Japan. Dev Biol Stand 89 331-332.
455. McDermott C, Grimsrud K, Waters J. A cellular pertussis vaccine and whole cell pertussis vaccine: a comparison of reported selected advers events (abst P41). In abstracts of the Third Canadian National Conference on Immunization, Calgary (Alberta) Canada, December 1988.
456. Scheifele D, Halperin S. Marked reduction in febrile seizures and hypotonic-hyporesponsive episodes with acellular pertussis-based vaccines: results of Canada-wide survellance (abstr 31). Paper presented at the 37th Annual Meeting of the Infectious Diseases Society of America, Philadelphia, PA. November 1999.
457. RT Chen, SC Rastogi, JR Mullen, et al. (1994) The Vaccine Adverse Event Reporting System (VAERS). Vaccine 12(6), 542-550.
458. S Rosenthal, R Chen and S Hadler (1996) The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med 150(5), 457-460.
459. MM Braun, GT Mootrey, ME Salive, et al. (2000) Infant immunization with acellular pertussis vaccines in the United States: assessment of the first two years’ data from the Vaccine Adverse Event Reporting System (VAERS). Pediatrics 106(4), E51.
460. ME Pichichero, MA Deloria, MB Rennels, et al. (1997) A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 100(5), 772-788.
461. HJ Schmitt, K Beutel, A Schuind, et al. (1997) Reactogenicity and immunogenicity of a booster dose of a combined diphtheria, tetanus, and tricomponent acellular pertussis vaccine at fourteen to twenty-eight months of age. J Pediatr 130(4), 616-623.
462. MB Rennels, MA Deloria, ME Pichichero, et al. (2000) Extensive swelling after booster doses of acellular pertussis-tetanus-diphtheria vaccines. Pediatrics 105(1), e12.
463. JG Liese, S Stojanov, TH Zink, et al. (2001) Safety and immunogenicity of Biken acellular pertussis vaccine in combination with diphtheria and tetanus toxoid as a fifth dose at four to six years of age. Munich Vaccine Study Group. Pediatr Infect Dis J 20(10), 981-988.
464. ME Pichichero, KM Edwards, EL Anderson, et al. (2000) Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children. Pediatrics 105(1), e11.
465. MB Rennels, MA Deloria, ME Pichichero, et al. (2002) Lack of consistent relationship between quantity of aluminum in diphtheria-tetanus-acellular pertussis vaccines and rates of extensive swelling reactions. Vaccine 20(Suppl 20), S44-S47.
466. S Isomura (1988) Efficacy and safety of acellular pertussis vaccine in Aichi Prefecture, Japan. Pediatr Infect Dis J 7(4), 258-262.
467. M Blennow and M Granstrom (1989) Adverse reactions and serologic response to a booster dose of acellular pertussis vaccine in children immunized with acellular or whole-cell vaccine as infants. Pediatrics 84(1), 62-67.
468. L Diggle and J Deeks (2000) Effect of needle length on incidence of local reactions to routine immunisation in infants aged 4 months: randomised controlled trial. BMJ 321(7266), 931-933.
469. J Nagel, D Svec, T Waters and P Fireman (1977) IgE synthesis in man. I. Development of specific IgE antibodies after immunization with tetanus-diphtheria (Td) toxoids. J Immunol 118(1), 334-341.
470. A Mark, B Bjorksten and M Granstrom (1995) Immunoglobulin E responses to diphtheria and tetanus toxoids after booster with aluminium-adsorbed and fluid DT-vaccines. Vaccine 13(7), 669-673.
471. S Hedenskog, B Bjorksten, M Blennow, et al. (1989) Immunoglobulin E response to pertussis toxin in whooping cough and after immunization with a whole-cell and an acellular pertussis vaccine. Int Arch Allergy Appl Immunol 89(2–3), 156-161.
472. CM Ausiello, F Urbani, A la Sala, et al. (1997) Vaccine- and antigen-dependent type 1 and type 2 cytokine induction after primary vaccination of infants with whole-cell or acellular pertussis vaccines. Infect Immun 65(6), 2168-2174.
473. DW Scheifele, SA Halperin and AC Ferguson (2001) Assessment of injection site reactions to an acellular pertussis-based combination vaccine, including novel use of skin tests with vaccine antigens. Vaccine 19(32), 4720-4726.
474. DW Scheifele, SA Halperin, JJ Ochnio, et al. (2005) A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Pediatr Infect Dis J 24(12), 1059-1066.
475. M Knuf, P Habermehl, J Faber, et al. (2006) Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life. Vaccine 24(27–28), 5627-5636.
476. WA Keitel, LR Muenz, MD Decker, et al. (1999) A randomized clinical trial of acellular pertussis vaccines in healthy adults: dose-response comparisons of 5 vaccines and implications for booster immunization. J Infect Dis 180(2), 397-403.
477. Decker MD, Cates KL, Maida A. Safety and immunogenicity in adults and adolescents of Biocine acellular pertussis(aP) vaccine abstr 123.002. In Abstract of the 7th International Congress for Infectious Diseases, Hong Kong, June, 1996.
478. KM Edwards, MD Decker, BS Graham, et al. (1993) Adult immunization with acellular pertussis vaccine. JAMA 269(1), 53-56.
479. RD Sekura, YL Zhang, R Roberson, et al. (1988) Clinical, metabolic, and antibody responses of adult volunteers to an investigational vaccine composed of pertussis toxin inactivated by hydrogen peroxide. J Pediatr 113(5), 806-813.
480. K Stehr, S Lugauer and U Heninger (1995) Immunogenicity and reactogenicity of Lederle/Takeda acellular pertussis vaccine in 185 German adults. Pediatr Res 37 189A.
481. Keitel W. Adult pertussis study results using five acellular vaccines. Acellular pertussis vaccine trials: results and impact on US public health. Paper presented at the National Institutes of Health Pertussis Conference, Washington, DC, June 3–5, 1996.
482. KD Forsyth, M Campins-Marti, J Caro, et al. (2004) New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 39(12), 1802-1809.
483. K Forsyth, M Nagai, A Lepetic and E Trindade (2005) Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24(5 Suppl), S93-S97.
484. CH Wirsing von Konig, M Campins-Marti, A Finn, et al. (2005) Pertussis immunization in the global pertussis initiative European region: recommended strategies and implementation considerations. Pediatr Infect Dis J 24(5 Suppl), S87-S92.
485. Tan T, Halperin S, Cherry J, et al. Pertussis immunization in the global pertussis initiative North American region: recommended strategies and implementation considerations. Pediatr Infect Dis (5 Suppl):S83–S86, 2005.
486. DGJ Caro, WE-HK Payne and OB JA (2005) Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis (5 Suppl), S75-S82.
487. S Plotkin (2005) The global pertussis initiative: process overview. Pediatr Infect Dis (5 Suppl), S7-S9.
488. T Tan Forsyth and CH vK (2005) Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis S69-S74.
489. S Plotkin (2005) Aims, scope and findings of the global pertussis initiative 24(5 suppl), S5-S6.
490. J Caro and DGK Payne (2005) Economic burden of pertussis and the impact of immunization. Pediatr Infect Dis 24(suppl 5), S48-S54.
491. D Greenberg and CH von Konig (2005) Heininger Health burden of pertussis in infants and children. Pediatr Infect Dis 24(5 Suppl), S39-S43.
492. D LM Pichichero and D Johnson (2006) An adolescent and adult formulation combined tetanus, diphtheria and five-component pertussis vaccine. Vaccine 5(2), 175-187.
493. M Blatter Pichichero and JHK WA (2006) Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics 117(4), 1084-1093.
494. ME Pichichero, MB Rennels, KM Edwards, et al. (2005) Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA 293(24), 3003-3011.
495. F Zepp, M Knuf, P Habermehl, W Mannhardt-Laakmann, B Howe and LR Friedland (2006 Nov) Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine. J Pediatr 149(5), 603-610.
496. S Halperin (2006) How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine. Pediatr Infect Dis 25(3), 195-200.
497. Ward J. Acellular pertussis vaccines in adolescents and adults [abstr 1291]. In Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 16–19, 2001, p 520.
498. SW Wright, KM Edwards, MD Decker and MM Lamberth (1994) Pertussis seroprevalence in emergency department staff. Ann Emerg Med 24(3), 413-417.
499. SA Halperin (2007 Jan 11) The control of pertussis—2007 and beyond. N Engl J Med 356(2), 110-113.
500. SA Halperin (2006 Nov) Recommendation for an adolescent dose of tetanus and diphtheria toxoids and acellular pertussis vaccine: reassurance for the future. J Pediatr 149(5), 589-591.
501. R Karen (2006) Broder M, Margaret M. et al. Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines. MMWR 55(RR-3), 1-50.
502. Preventing Tetanus Diphtheria, and Pertussis Among Adults Use of to diagnose pertussis (66). Use of PCR tests with low specificity can result in unnecessary investigation and treatment of persons with false-positive PCR test. www.cdc.gov/mmwr/preview/mmwrhtml/rr5517a1.htm?s_cid=rr5517a1_e
503. Canada Immunization Guide (2002) PPHBH Canada (Eds) 6th ed. Ottawa, (Ontario), Canada: National Advisory Committee on Immunization
504. A Shefer, L Dales, M Nelson, et al. (1995) Use and safety of acellular pertussis vaccine among adult hospital staff during an outbreak of pertussis. J Infect Dis 171(4), 1053-1056.
505. CD Christie, KM Garrison, L Kiely, et al. (2001) A trial of acellular pertussis vaccine in hospital workers during the Cincinnati pertussis epidemic of 1993. Clin Infect Dis 33(7), 997-1003.
506. MD Decker and KM Edwards (1996) Acellular pertussis vaccines: the authors reply. N Engl J Med 334 1547-1548.